A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer

Part of paid clinical trials in Fairfax, Virginia.

Sponsor
Inova Health Care Services
Study ID
NCT06007846
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Namenda — DRUG
    Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily

Study Details

This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy. In addition to the primary endpoint and multiple secondary efficacy endpoints, we will describe changes in quality of life on treatment over time.

Key Dates

Start date
Jul 31, 2023
Status verified
Sep 2025
Primary completion
Jul 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1

Primary Outcome Measure

Patients Progression Free Survival at 6 months [ Time Frame: 6 months from the start of treatment ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Inova Schar Cancer InstituteFairfaxVirginia22031
Elahe Mollapour
Keary Jane't
Arthur Winer, MD (PRINCIPAL_INVESTIGATOR)
Inova Health Care ServiceFalls ChurchVirginia22042
Elahe Mollapour
[email protected]
571-472-0615
Keary Jane't
[email protected]
571-472-3173
Arthur Winer (PRINCIPAL_INVESTIGATOR)

Find similar trials in Fairfax, VA

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
Inova Schar Cancer Institute· Fairfax, VAInova Health Care Service· Falls Church, VA

Related Studies